Dermatology Life Quality Indexprovides different information from PASI
Washington - The Dermatology Life Quality Index (DLQI) is a widely used and validated measure of patient-reported outcomes in psoriasis. Unlike the Psoriasis Area Severity Index (PASI) score, a well-established measure of a patient's disease activity where each area of the body is weighted proportionally to the surface area covered, the DLQI is more heavily influenced by areas of the body that are readily visible, such as the head and lower extremities. "Therefore, the DLQI may provide information regarding outcomes beyond that described by the PASI score," said Alexa B. Kimball, M.D., M.P.H., assistant professor of dermatology at Stanford University.
For Healthy Skin Month, a dermatologist discusses winter sun protection, overlooked patients in skin cancer screening, bemotrizinol, and AI in detection.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Jessica Mercer, MD, debated severity scoring, trial data, and monitoring when selecting JAK inhibitors for alopecia areata.
For Healthy Skin Month, a dermatology nurse practitioner shares why sunscreen matters in winter and how clinicians can close gaps in skin cancer screening.
Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.
FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.